Biomarkers in chronic obstructive pulmonary disease.

Currently, with exception of lung function tests, there are no well validated biomarkers or surrogate endpoints that can be used to establish efficacy of novel drugs for chronic obstructive pulmonary disease (COPD). However, the lung function test is not an ideal surrogate for short-term drug trials because it (1) does not provide information regarding disease activity or the underlying pathologic process, (2) cannot separate the various phenotypes of COPD, (3) is not specific for COPD, and (4) is relatively unresponsive to known therapies that prolong survival. Accordingly, there are large-scale studies presently underway to identify novel biomarkers in COPD. In this article, we discuss the current barriers of biomarker discovery and propose possible criteria and methods for developing novel biomarkers in COPD.

[1]  Angshu Bhowmik,et al.  Airway and systemic inflammation and decline in lung function in patients with COPD. 2005. , 2009, Chest.

[2]  L. Edwards,et al.  Serum surfactant protein D is steroid sensitive and associated with exacerbations of COPD , 2009, European Respiratory Journal.

[3]  J. Blalock,et al.  Induction of lung emphysema is prevented by L‐arginine‐threonine‐arginine , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[4]  L. Edwards,et al.  Evaluation of serum CC-16 as a biomarker for COPD in the ECLIPSE cohort , 2008, Thorax.

[5]  M Cazzola,et al.  Outcomes for COPD pharmacological trials: From lung function to biomarkers. , 2008, Revista portuguesa de pneumologia.

[6]  W. MacNee,et al.  Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE) , 2008, European Respiratory Journal.

[7]  D. Smallwood,et al.  Serum amyloid a is a biomarker of acute exacerbations of chronic obstructive pulmonary disease. , 2008, American journal of respiratory and critical care medicine.

[8]  D. Postma,et al.  Increased systemic inflammation is a risk factor for COPD exacerbations. , 2008, Chest.

[9]  I. Olafsson,et al.  Gender differences in the association between C-reactive protein, lung function impairment, and COPD , 2007, International journal of chronic obstructive pulmonary disease.

[10]  R. Stockley,et al.  Inter-relationships between inflammatory markers in patients with stable COPD with bronchitis: intra-patient and inter-patient variability , 2007, Thorax.

[11]  R. Garrod,et al.  The relationship between inflammatory markers and disability in chronic obstructive pulmonary disease (COPD). , 2007, Primary care respiratory journal : journal of the General Practice Airways Group.

[12]  H. Coxson,et al.  Antielastin autoimmunity in tobacco smoking–induced emphysema , 2007, Nature Medicine.

[13]  Bartolome Celli,et al.  Profiling serum biomarkers in patients with COPD: associations with clinical parameters , 2007, Thorax.

[14]  Bartolome Celli,et al.  Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. , 2007, The New England journal of medicine.

[15]  S. Bojesen,et al.  C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease. , 2007, American journal of respiratory and critical care medicine.

[16]  John R Hurst,et al.  Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease. , 2006, American journal of respiratory and critical care medicine.

[17]  N. Anthonisen,et al.  C-reactive protein and mortality in mild to moderate chronic obstructive pulmonary disease , 2006, Thorax.

[18]  J. Legge,et al.  ABC of chronic obstructive pulmonary disease. Diagnosis. , 2006, BMJ.

[19]  D. Sin,et al.  Emerging drugs for the treatment of chronic obstructive pulmonary disease , 2006, Expert opinion on emerging drugs.

[20]  P. Jones,et al.  Outcomes and markers in the assessment of chronic obstructive pulmonary disease , 2006, European Respiratory Journal.

[21]  H Tunstall-Pedoe,et al.  Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. , 2005, JAMA.

[22]  T. Seemungal,et al.  Airway and Systemic Inflammation and Decline in Lung Function in Patients With COPD , 2005, Chest.

[23]  N. Anthonisen,et al.  Bronchodilator response in the lung health study over 11 yrs , 2005, European Respiratory Journal.

[24]  N. Anthonisen,et al.  Contemporary management of chronic obstructive pulmonary disease: scientific review. , 2003, JAMA.

[25]  P. Sterk,et al.  Standardised methodology of sputum induction and processing. Future directions. , 2002, The European respiratory journal. Supplement.

[26]  D. DeMets,et al.  Considerations in the evaluation of surrogate endpoints in clinical trials. summary of a National Institutes of Health workshop. , 2001, Controlled clinical trials.

[27]  B. Nordestgaard,et al.  Elevated plasma fibrinogen associated with reduced pulmonary function and increased risk of chronic obstructive pulmonary disease. , 2001, American journal of respiratory and critical care medicine.

[28]  G. Guyatt,et al.  Users' guides to the medical literature: XIX. Applying clinical trial results. A. How to use an article measuring the effect of an intervention on surrogate end points. Evidence-Based Medicine Working Group. , 1999, JAMA.

[29]  Alan D. Lopez,et al.  Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease Study , 1997, The Lancet.

[30]  J. Donohue.  Management of chronic obstructive pulmonary disease. , 1995, Current opinion in pulmonary medicine.

[31]  J. Hosenpud,et al.  Abnormal pulmonary function specifically related to congestive heart failure: comparison of patients before and after cardiac transplantation. , 1990, The American journal of medicine.

[32]  D. Sin,et al.  The Effects of Fluticasone With or Without Salmeterol On Systemic Biomarkers of Inflammation in COPD , 2008 .